Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review - Top-Institutions - MDSpire

Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review

  • By

  • Fang Lu

  • Yi Li

  • Yaqian Zhu

  • Wenkang Zong

  • Fang Zhao

  • Yongxiang Zhang

  • Liheng Yang

  • Yuechuan Li

  • July 6, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Tianjin Chest Hospital
    Tianjin Chest Hospital

    Tianjin, Tianjin

    Key Differentiators

    • Oncology

  • #2

    Hospital Grosshansdorf
    Hospital Grosshansdorf

    Grosshansdorf, Germany

    Key Differentiators

    • Oncology

  • #3

    Yale Cancer Center
    Yale Cancer Center

    New Haven, Connecticut

    Key Differentiators

    • Oncology

  • #4

    AdventHealth Cancer Institute
    AdventHealth Cancer Institute

    Orlando, Florida

    Key Differentiators

    • Oncology

  • #5

    Winship Cancer Institute at Emory University
    Winship Cancer Institute at Emory University

    Atlanta, Georgia

    Key Differentiators

    • Oncology

Original Source(s)

Two cases of pancytopenia characterized by severe neutropenia induced by anti-PD-1 tislelizumab combined with chemotherapy in non-small cell lung cancer patients and a literature review

  • by Fang Lu, Yi Li, Yaqian Zhu, Wenkang Zong, Fang Zhao, Yongxiang Zhang, Liheng Yang, Yuechuan Li

  • July 6, 2026

Related Content

Distribution analysis of gynecological carcinomas with concurrent second primary carcinomas

Correction: miR-1323 promotes cell migration in lung adenocarcinoma by targeting Cbl-b and is an early prognostic biomarker

Efficacy of Jishi Shuanghua Granules in preventing radiation-induced esophagitis in non-small cell lung cancer patients undergoing concurrent chemoradiotherapy: protocol for a multicenter, randomized, double-blind, placebo-controlled trial